← Back to Clinical Trials
Recruiting NCT03655015

NCT03655015 Patient-derived Organoid Model and Circulating Tumor Cells for Treatment Response of Lung Cancer

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT03655015
Status Recruiting
Phase
Sponsor The University of Texas Health Science Center at San Antonio
Condition Lung Neoplasm
Study Type OBSERVATIONAL
Enrollment 150 participants
Start Date 2018-10-16
Primary Completion 2028-12-01

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
Lung Tumor Resection

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 150 participants in total. It began in 2018-10-16 with a primary completion date of 2028-12-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Create a living biobank of PDOs from Stage I-III lung cancer patients.

Eligibility Criteria

Inclusion Criteria: * Read, consented to and signed the IRB-approved informed consent form prior to any study related procedure. * Diagnosis of lung cancer or lung mass or lymphadenopathy that will either systemic treatment or tumor resection as part of standard of care * Any clinical stage of lung cancer * Adult patients ≥18 years of age * Able and willing to complete a questionnaire on their environmental/occupational exposures and smoking/alcohol history Exclusion Criteria: * At the discretion of the treating physician, patient will not be able to fulfill the requirements of the study.

Contact & Investigator

Central Contact

Josephine Taverna, MD

✉ tavernaj@uthscsa.edu

📞 210-450-8234

Principal Investigator

Josephine Taverna, MD

PRINCIPAL INVESTIGATOR

UT Health San Antonio M.D. Anderson Cancer Center

Frequently Asked Questions

Who can join the NCT03655015 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Lung Neoplasm. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT03655015 currently recruiting?

Yes, NCT03655015 is actively recruiting participants. Contact the research team at tavernaj@uthscsa.edu for enrollment information.

Where is the NCT03655015 trial being conducted?

This trial is being conducted at San Antonio, United States.

Who is sponsoring the NCT03655015 clinical trial?

NCT03655015 is sponsored by The University of Texas Health Science Center at San Antonio. The principal investigator is Josephine Taverna, MD at UT Health San Antonio M.D. Anderson Cancer Center. The trial plans to enroll 150 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology